Press release
Small Form Factor Device Simplicity Propelling the Adoption of Self-administered Subcutaneous Infusion
(Amherst, NH) – In terms of developer interest and market activity, small form factor subcutaneous infusion (SFFSI) devices are reaching a tipping point that is forcing the industry at-large to take notice and re-assess their product strategies accordingly. While there are currently two dozen products launched and in development, the presence of large pharmaceutical companies in this space and the strategic agreements in place with key SFFSI device developers indicates that the approach has found important advocates.Capabilities such as compact device designs, flexible cannula insertion, variable dosing and drug cartridge replacement have positioned these devices squarely within the home healthcare space. Ease-of-use features such as intuitive infusion activation, strategic button placement, digital displays and tactile feedback cues further enhance the feeling of assurance and wellbeing among users.
Since existing infusibles are typically supplied in vials or IV containers, often as concentrates for dilution or as lyophilized powders, the transition from caregiver administration to self-administration requires device designers and drug developers to adapt as-supplied packaging to accommodate the SFFSI primary container. For powder drugs, formulators are often challenged to create a solution version of the drug. If this is not an attractive option, the device designer is called upon to simplify the reconstitution step and integrate it as seamlessly as possible into the overall device operational envelope. This latter approach is used by Enable Injections. The Company’s SFFSI device utilizes a vial transfer system integrated with its device fill station to reconstitute the drug just prior to filling. The device is currently being developed for several therapeutic drugs under an agreement with CSL Behring.
The evolving market for small form factor subcutaneous infusion devices is detailed in a new and comprehensive report researched and written by Greystone Research Associates. Small Form Factor Subcutaneous Infusion Systems analyzes the global market for these innovative devices that have been specifically designed to address a growing, unmet market need. The report also assesses key therapeutic market segments, analyzes demand drivers, development factors, market considerations, and economic factors, and provides profiles of market sector participants.
More information is available at http://www.greystoneassociates.org
Source: Greystone Research Associates
About Greystone
Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Contact:
Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Small Form Factor Device Simplicity Propelling the Adoption of Self-administered Subcutaneous Infusion here
News-ID: 342117 • Views: …
More Releases from Greystone Research Associates
Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration…
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors.
A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when…
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population.
To fully address the unmet need these technologies…
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from…
More Releases for SFFSI
Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration…
